super console x2 pro game list
Prime Minister Muhammad Shehbaz Sharif has said Pakistan stood united with the global community in reaffirming its firm commitment to strengthening the national HIV response and ensuring that no one was left behind. The theme, “Take the Rights Path : My health, My right,” reminds us that the journey to eliminate AIDS as a public health threat begins with a firm commitment to human rights, the prime minister said in a message in connection with World AIDS Day 2024. He said upholding the United Nations Declaration on Human Rights and promoting the inclusion of all communities were essential for eradicating AIDS as a public health threat. “Healthcare is a fundamental right. Through our collective efforts, we will ensure that all our citizens enjoy this fundamental right in an equitable manner. By working together, we will continue to strengthen our health systems and expand access to essential services for our citizens,” the prime minister added. He highlighted that HIV/AIDS remained a health challenge and a significant socio-economic issue that threatened livelihoods, disrupts families, and deepens inequalities. Gaps in testing and treatment coverage call for deep introspection – a call to reach the most vulnerable, making strategies to be truly responsive to those at risk, and ensuring that our policies evolve to meet the shifting dynamics of the epidemic. “Despite our collective efforts, the HIV epidemic in Pakistan continues to grow, underscoring the need for bold, innovative, and sustainable interventions. It is only through the strategy rooted in equality and inclusion that we can halt the spread of HIV. Strong political will, effective leadership, and enhanced financial commitments are essential to implementing a rights-based national HIV strategy,” he remarked. PM Shehbaz Sharif emphasized that the urgent challenges that needed our attention were eliminating spread of HIV/AIDS through needle sharing among people who inject drugs, safe blood transfusion, and eliminating mother-to-child HIV transmission. We must also address the vulnerabilities of marginalized groups, particularly adolescent girls and young women, who face heightened risks of HIV infection. “On this World AIDS Day, let us stand united to ‘take the rights path’ towards an AIDS-free Pakistan. A future free from AIDS can only be achieved through collective action that upholds human dignity, equity, and inclusion,” he said adding, “Let us act decisively and compassionately, empowering those most affected by HIV to lead the way. Together, we can safeguard the health and well-being of our future generations and build a healthier and just society for all”.BOSTON (AP) — Boston Celtics center Kristaps Porzingis is slated make his season debut Monday night against the Los Angeles Clippers following offseason ankle surgery. The 7-foot-2 Latvian center was upgraded from probable to available about an 90 minutes before tipoff, though Celtics coach Joe Mazzulla said how much he'd play was to be determined. Veteran center Al Horford, who has started 14 of the Celtics 17 games this season, is out Monday with an illness. Fellow big man Luke Kornet is also sitting out as he continues to deal with hamstring tightness. “He has worked hard, he's in good shape. We'll put him in position to be healthy and be successful and do what's best for the team,” Mazzulla said. “He's been pretty consistent, just based on his work ethic and what he's done to get to this point.” Porzingis had surgery to fix a tear in the tissue that holds the ankle tendons in place. The issue limited him to seven playoff games during the Celtics' NBA championship run last season. Boston is 14-3 this season, but has missed his presence on the inside, with teams routinely outscoring the defending champions in the paint. Mazzulla acknowledged that how Porzingis plays on the offensive end, particularly how he operates sometimes out of the high and low post, will force some adjustment from how the team has played this season without him on the floor. “I think last year we had an opportunity to see how teams were guarding him,” Mazzulla said. "That'll take a little bit of time to figure out what the coverages are, just get used to that spacing. That'll take some time. ... Then we'll figure out how we go from there." The original window for Porzingis' return following surgery was five to six months. But Celtics president of basketball operations Brad Stevens said before the season that they didn't want to hold to a specific timeline because of the uniqueness of the injury. Porzingis injured his ankle in Game 2 of the NBA Finals against the Dallas Mavericks and missed the next two games. He returned for Game 5, contributing five points and one rebound in 16 minutes as the Celtics beat Dallas 106-88 to clinch their record 18th title. Porzingis averaged 20 points and seven rebounds in 57 games for last season. He signed a $60 million, two-year extension with Boston in the summer of 2023 after the Celtics acquired him in a trade with Washington. AP NBA: https://apnews.com/hub/nbaRally House Opens New Arkansas Storefront in Fort Smith
Sirtautas gave the Highlanders the lead for good with 2:38 left in the extra period. Moss shot 4 of 13 from the field, including 2 for 7 from 3-point range, and went 5 for 6 from the line for the Highlanders (9-2). Josiah Harris scored 12 points and added five rebounds. Achile Spadone led the Bison (4-7) in scoring, finishing with 22 points and two steals. Bucknell also got 19 points and four assists from Josh Bascoe. Noah Williamson had nine points. Bascoe's layup with 12 seconds left forced overtime tied at 59. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
The No. 12 Clemson Tigers and the No. 14 South Carolina Gamecocks face off in the Palmetto Bowl. If you are looking to find Tigers vs. Gamecocks tickets, information is available below. Clemson vs. South Carolina game info How to buy Clemson vs. South Carolina tickets for college football Week 14 You can purchase tickets to see the Tigers square off against the Gamecocks from multiple sources. Clemson vs. South Carolina betting odds, lines, spreads Odds courtesy of BetMGM Clemson Tigers schedule Clemson Tigers stats South Carolina Gamecocks schedule South Carolina Gamecocks stats This content was created for Gannett using technology provided by Data Skrive.Ariana Grande explains the viral 'holding space' moment with Cynthia Erivo
Pitney Bowes director Paul J. Evans acquires $226,071 in common stock
The facts at hand suggest that the intersection is much more complicated, and Europe is on a slip road towards a spaghetti junction. At a moment of intense geopolitical upheaval and economic stagnation, the bloc is being squeezed from all sides, and from within. “The crisis theatres in Europe and Indo-Pacific are linked as we can witness from North Korea’s involvement in Russia’s war of aggression against Ukraine,” the EU’s outgoing top diplomat Josep Borrell said last month. 01:09 North Korea may send 100,000 troops to Russia, as Kim tells military to ‘go all out’ On the face of it, the EU could hardly be less ready for these external shocks: politically and economically, it is perpetually on the cusp of turmoil.TORONTO, ON / ACCESSWIRE / December 27, 2024 / SPETZ INC. (the "Company" or "Spetz") (CSE:SPTZ)(OTC Pink:DBKSF) is pleased to announce that it is arranging a private placement offering (the "Offering") of up to 5,000,000 Common Shares, at a price of $0.10 per share, for gross proceeds of up to $500,000. In addition, Spetz is proposing to settle an aggregate of $445,645.89 in accounts payable to arm's length parties by way of the issuance of 4,456,458 shares for debt at an issue price of 0.10 per share (the "Shares for Debt Transactions"), and is negotiating the restructuring of certain outstanding debt, in the aggregate principal amount of $1,017,673, consisting primarily of convertible debentures that have become due, as further described below (the "New Debentures"). The Company has been working on the foregoing initiatives for the past several weeks and believes that they are in the best interests of the Company. The Offering Spetz intends to close the Offering shortly. The proceeds from the Offering will be used for general working capital purposes and to seek additional business opportunities that will create value. Spetz does not anticipate any insider participation in the Offering, or the creation of a new insider or control person as a result of the closing of the Offering. No finder's fees or other compensation will be paid in connection with the Offering. Shares for Debt Transactions The Company is proposing to settle an aggregate of $445,645.89 of current payables to arm's length parties by the proposed issuance of a total of 4,456,458 shares, at an issue price of $0.10 per share. Spetz does not anticipate the creation of a new insider or control person as a result of the closing of the Shares for Debt Transactions. The closing of the Shares for Debt Transactions is anticipated to close concurrently with the Offering. New Debentures Spetz is working to issue new convertible debentures in the aggregate principal amount of $1,017,673, replacing primarily the principal amount of outstanding convertible debentures that have matured and are currently due and payable by Spetz. The principal amount of the new debentures would be convertible into units of the Company ("Units"), at a price per Unit of $0.20, with each Unit comprised of one (1) Common Share and one-half (1/2) of a common share purchase warrant ("Warrant"). Each whole Warrant would be exercisable for one Common Share, at a price of $0.40 per share, for a period of 24 months following the issuance of the Warrants. The New Debentures would be outstanding for a minimum of 18 months following the closing in order to allow Spetz to execute its business. Otherwise, the New Debentures would be unsecured obligations of the Company and bear interest at a rate of 12% per annum. Assuming conversion of the entire principal amount of the New Debentures, the Company would issue an aggregate of up to 5,088,365 Common Shares and up to 2,544,182 Warrants. The Company believes that the Offering, the Shares for Debt Transactions and the New Debentures are in the best interests of the Company, and the foregoing have been approved by the independent directors of the Company as well due to the fact that the completion of the proposed transactions, taken as a whole, would result in the issuance of more than 100% of the currently issued and outstanding Common Shares of Spetz, on a fully-diluted basis. Accordingly, as a result of the potential significant dilution of the Common Shares, the Company intends to issue the securities contemplated in the Offering, the Shares for Debt Transactions and the New Debentures without securityholder approval in reliance on the exceptions outlined in Section 4.6(2)(b) of CSE Policy 4, as the Company is in serious financial difficulty. The Company has explored several avenues to secure additional funding in order to continue ongoing operations and to service its outstanding debt obligations. To date, the Company has been unable to secure any such funding due to challenging capital markets conditions for venture issuers and the Company's current debt obligations. The Company recently secured some interim relief (see press release dated November 29, 2024) wherein the board of directors waived their compensation and the current holders of the outstanding secured debentures agreed to extend the maturity date from October 31, 2024 to December 31, 2024. The Company currently does not have sufficient funding to continue as a going concern, and therefore, if the proposed Offering, the Shares for Debt Transactions and the New Debentures are not completed, and no alternative arrangements are secured, there is significant doubt about the Company's ability to continue as a going concern. The Company's independent directors have also determined that the Offering, the Shares for Debt Transactions and the New Debentures are in the best interests of the Company and reasonable based on the Company's current financial circumstances in order keep the Company solvent. The Company's independent directors have determined that neither (i) seeking shareholder approval for the Offering, the Shares for Debt Transactions and the New Debentures nor (ii) a rights offering to existing securityholders on the same terms as the Offering would be feasible to complete, based on the Company's immediate liquidity requirements. All securities issued pursuant to the Offering, the Shares for Debt Transactions and the New Debentures will be subject to a statutory hold period expiring four months and one day after the closing of the Offering, the Shares for Debt Transactions and the New Debentures, respectively. Completion of the Offering, the Shares for Debt Transactions and the New Debentures is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals, including approval of the Canadian Securities Exchange. None of the securities issued in the Offering, the Shares for Debt Transactions or the New Debentures will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful. About Spetz Inc. Spetz Inc. is a multinational technology company that operates Spetz, a global online, AI-powered marketplace platform that dynamically connects consumers to nearby top-rated service providers in around 30 seconds. Spetz is available in the USA, United Kingdom, Australia, and Israel. The Spetz vision is to reinvent how people around the world connect to services in their moment of need. Connecting them immediately with the top-matched service provider for any need, anytime, anywhere. Spetz Website: www.spetz.app Spetz Investor information: https://investor.spetz.app/ Company Contacts: Investor Relations Email: Investors@spetz.app Phone: 647-956-6033 NEITHER THE CANADIAN SECURITIES EXCHANGE, NOR THEIR REGULATION SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary Note Regarding Forward-looking Statements Certain information herein constitutes "forward-looking information" as defined under Canadian securities laws, which reflect management's expectations regarding objectives, plans, goals, strategies, future growth, results of operations, performance, business prospects and opportunities of the Company. The words "plans", "expects", "does not expect", "scheduled", "estimates", "intends", "anticipates", "does not anticipate", "projects", "believes", or variations of such words and phrases or statements to the effect that certain actions, events or results "may", "will", "could", "would", "might", "occur", "be achieved", or "continue" and similar expressions identify forward-looking statements. Such forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable by management as of the date hereof, are inherently subject to significant business, economic and competitive uncertainties and contingencies. When relying on forward-looking statements to make decisions, the Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not the times at or by which such performance or results will be achieved. A number of factors could cause actual results to differ, possibly materially, from the results discussed in the forward-looking statements. SOURCE: Spetz Inc. View the original on accesswire.com
NFV Infrastructure Market Is Likely to Experience a Tremendous Growth in Near Future
NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Viking and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On November 3, 2024 , Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024 . However, analysts were quick to note that Viking may face production problems for VK2735, especially for 100mg or higher doses. Analysts at Deutsche Bank stated in a note that scaling up production for the drug "will be costly with capital requirements and expertise beyond what [Eli] Lilly (LLY) and Novo [Nordisk] (NVO) currently have[.]" Following these reports, Viking's stock price fell $9.74 per share, or 13.36%, to close at $63.14 per share on November 4, 2024 . Pomerantz LLP, with offices in New York , Chicago , Los Angeles , London , Paris , and Tel Aviv , is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud , breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com . Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLPSuspect in UnitedHealthcare CEO killing charged with murder in New York, court records showTrump wants pardoned real estate developer Charles Kushner to be ambassador to France